Trial Profile
Immunotherapy With MK-3475 in Locoregionally Advanced, Surgically Resectable Head and Neck Squamous Cell Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 May 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Cisplatin
- Indications Carcinoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 09 Dec 2022 Planned End Date changed from 5 Apr 2022 to 31 Dec 2025.
- 09 Dec 2022 Status changed from completed to active, no longer recruiting.
- 27 Aug 2021 Planned End Date changed from 31 Dec 2021 to 5 Apr 2022.